Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 7/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171337 | 1.00 | MTNR1B (0.50) | MTNR1BMTNR1APOLBSMN1; SMN2S1PR1 | |
| SCHEMBL1373013 | 0.91 | HRH3 (0.49) | MTNR1BMTNR1APOLBSMN1; SMN2S1PR1 | |
| SCHEMBL1371910 | 0.91 | F2 (0.46) | MTNR1BMTNR1APOLBSMN1; SMN2S1PR1 | |
| SCHEMBL2170066 | 0.91 | F2 (0.46) | MTNR1BMTNR1APOLBSMN1; SMN2S1PR1 | |
| SCHEMBL1371657 | 0.89 | F2 (0.44) | MTNR1BMTNR1AS1PR1CYP2C9MMP13 | |
| SCHEMBL1371656 | 0.88 | S1PR1 (0.53) | POLBSMN1; SMN2S1PR1CYP2C9CYP3A4 | |
| SCHEMBL1373946 | 0.87 | S1PR1 (0.52) | S1PR1CYP2C9MMP13CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL1375216 | 0.86 | S1PR1 (0.52) | S1PR1CYP2C9MMP13CYP3A4CYP2D6 | |
| SCHEMBL1371552 | 0.85 | S1PR1 (0.48) | S1PR1CYP2C9MMP13CYP3A4CYP2D6 | |
| SCHEMBL2173417 | 0.84 | S1PR1 (0.49) | SMN1; SMN2S1PR1CYP2C9MMP13CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | MTNR1B 1217/4885MTNR1A 1361/4885POLB 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.